Effect of Anti-Angiogenesis/Immunotherapy Combo in Poor-Risk RCC

Findings from a planned subanalysis of  IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology.

Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news